General Information

Mail: University of Houston
Cullen College of Engineering
E421 Engineering Bldg 2, Houston, TX 77204-4007
Map & Driving Directions (includes parking information)
Email: info [at] egr [dot] uh [dot] edu

News

Yokogawa Corp. Donates $5k for Undergraduate Scholarship Support

Printer-friendly versionSend by emailPDF version
Josh Butler and Sebastien Chambert

Headquartered just 20 miles southwest of downtown Houston, Texas, Yokogawa Corporation of America has sales offices across the United States. Commitment to their customers is the number one priority, and they back it up with a network of representatives and distributors that reflect this commitment.

The parent company, Yokogawa Electric Corporation, is dedicated to developing the most advanced control and instrumentation products and systems in the world. Today, Yokogawa has a firm hold on its position as a leading manufacturer in the fields of measurement, control, and information. As a major global player, the company anticipates the needs of the times, continually tackling new challenges and exploring new markets in order to provide the best solutions in the world.

On September 13, 2013, Yokogawa Corporation of America became a corporate partner with the University of Houston Cullen College of Engineering. The college’s Director of Development, Joshua Butler was presented with a check in the amount of $5,000 from Vice President of Finance and Business Service, North America, Sebastien Chambert to benefit undergraduate scholarship support for a student majoring in chemical or electrical engineering. The scholarship will provide a deserving student to cover expenses such as tuition, books, fees, and/or supplies for the current academic semester.

For more information about Yokogawa Corporation of America, please visit: http://www.yokogawa.com/us/cp/aboutus/us-ykgw-corporateoverview.htm.

Department: 

Related News Stories

Researcher Publishes Paper on Engineered Antibody that Targets Acute Myeloid Leukemia

Almost 19,000 new cases of acute myeloid leukemia and 10,500 deaths from the blood and bone marrow cancer could strike Americans this year, according to the American Cancer Society. Chemotherapy, when used as primary treatment, is successful in about 65 percent of patients with the cancer, and remission rates vary depending on patients’ individual characteristics, according to the organization.

Upcoming Events / Seminars

Archived News